GlassScriptPhysician profile
Rizwan Asif Malik
NPI 1609007582
$3,152.10
in general payments reported to CMS, 2019-2025
23 companies · $220 in 2025
The $220 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2021: $198 · 2022: $1,610 · 2023: $494 · 2024: $445 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,158.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $1,274.22 | 2022 | |
| Glaxosmithkline, LLC. | $346.16 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.24 | 2021-2024 | Ofev |
| Astrazeneca Pharmaceuticals LP | $268.64 | 2019-2024 | Fasenra, Tezspire, Airsupra |
| Jazz Pharmaceuticals INC. | $185.36 | 2021-2023 | |
| Genzyme Corporation | $137.68 | 2023-2024 | |
| Intuitive Surgical, INC. | $94.53 | 2025 | |
| Genentech USA, INC. | $90.90 | 2019 | |
| Amgen INC. | $70.80 | 2024-2025 | Tezspire |
| Mylan Specialty L.P. | $65.30 | 2022-2024 | Yupelri |
| Avadel Cns Pharmaceuticals, LLC | $54.48 | 2023-2024 | Lumryz |
| Boston Scientific Corporation | $47.08 | 2022 | |
| Electromed, INC. | $37.64 | 2023-2024 | Smartvest |
| Vapotherm INC | $34.66 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.57 | 2023-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $23.39 | 2025 | Sunosi |
| Breas Medical, INC. | $23.24 | 2025 | Vivo 1/2, Vivo 45 Ls |
| Takeda Pharmaceuticals U.S.A., INC. | $22.79 | 2024 | Hyqvia |
| Fisher & Paykel Healthcare INC | $18.18 | 2024 | Fisher & Paykel Healthcare |
| E.R. Squibb & Sons, L.L.C. | $16.61 | 2023 | Eliquis |
| La Jolla Pharmaceutical Company | $14.37 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11.26 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rizwan Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.